Acquired Bone Marrow Aplasia, Alopecia, Atopic Dermatitis, Autoimmune Diseases, Autoimmune Thyroiditis, Gvhd, Inflammatory Disease, Multiple Sclerosis, Rheumatoid Arthritis, Systemic Lupus Erythematosus, Vitiligo
Conditions
Keywords
Autoimmune Diseases, Inflammation, Graft vs Host Disease, T-lymphocytes, Regulatory, Interleukin-2
Brief summary
Interleukin 2 (IL-2) is a critical cytokine for the survival and function of regulatory T cells (LTreg). This cytokine has a dual role in the immune system. IL-2 stimulates immune responses by acting on the intermediate affinity IL-2R receptor, IL-2Rβγ, expressed by conventional T cells (LTconv) during activation, but also contributes to the inhibition of immune responses via LTreg that express the high affinity receptor IL-2Rαβγ. This difference in IL-2 receptor affinity for IL-2 has led to the development of low-dose IL-2 therapy to stimulate LTreg and improve control of excessive inflammation in autoimmune (AID), inflammatory or alloimmune diseases Low-dose IL-2 therapy is being studied in several of these diseases such as systemic lupus erythematosus, type 1 diabetes, alopecia, HCV (hepatitis C virus)-induced vasculitis, atopic dermatitis and chronic allo-transplantation-related graft-versus-host disease (GVHD). Some of these studies have shown an increase in LTreg numbers and an improvement in certain clinical signs. To improve LTreg targeting in autoimmune diseases, inflammatory diseases or GVHD, mutated IL-2s (muteins) have been developed with selective LTreg agonist properties. These IL-2 muteins are linked to an Fc fragment to increase their half-life. Two IL-2 variants (IL-2Vs)-Fc preferentially stimulate STAT5 phosphorylation in LTregs compared to conventional FoxP3- (LTconv) CD4+ or CD8+ T cells
Detailed description
Hypothesis: In order to confirm that this differential effect of IL-2 muteins, already established in non-diseased controls, is also observed in patients with autoimmune diseases, inflammatory diseases or GVHD, a pilot in vitro study should be conducted on a small number of patient's blood samples (5 or 10 depending on the pathology). Objective : Conduct a multicentre pilot study to confirm the hypothesis that IL-2 muteins preferentially activate the STAT5 pathway in LTreg compared to LTconv in patients with GVHD, acquired bone marrow aplasia, systemic lupus erythematosus, multiple sclerosis, rheumatoid arthritis, autoimmune thyroiditis, vitiligo, alopecia or atopic dermatitis Method: At the inclusion, patients will have a blood sample collected for in vitro research purposes. Their clinical data will also be collected. Conclusion This trial should provide in vitro proof-of-principle of the efficacy of IL-2 muteins on LTreg and could eventually lead to a therapeutic trial
Interventions
OTHERBlood sample taken at a single time point
At inclusion, a blood sample will be taken for research purpose
Sponsors
Assistance Publique - Hôpitaux de Paris
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE
Intervention model description
This study is a multicenter, open-label, non-controlled, non-randomized in vitro study.
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Inclusion criteria common to all patients in different departments: * Age18 years * Affiliated to social security or entitled to * Patient who has been informed of the study and has signed a free and informed consent Inclusion criteria specific by department: Inclusion criteria for Clinical Hematology Department: * Patient with GVHD following allogeneic hematopoietic stem cell transplantation (HSC) * Or with acquired bone marrow suppression * Lymphocytosis \> 0.5 G/L Inclusion criteria for Nephrology and Transplantation department: \- Patient with systemic lupus erythematosus (ACR classification criteria) Inclusion criteria for Neurology department: \- Patient with multiple sclerosis (criteria of Mc Donald 2017) Inclusion criteria for Rheumatology Department: \- Patient with rheumatoid arthritis (ACR classification criteria) Inclusion criteria for Internal Medicine-Endocrinology Department: \- Patient with Basedow disease, Hashimoto's thyroiditis Inclusion criteria for Dermatology Department: \- Patient with vitiligo or alopecia areata or atopic dermatitis
Exclusion criteria
Non-inclusion criteria common to all patients: * Patient under guardianship, curatorship or judicial protection * Pregnant, parturient or breastfeeding woman * Patient deprived of liberty * Patient hospitalized without consent * Patient admitted to a health or social institution for purposes other than research * Minor patient * Adult patient unable to express consent * Refusal to participate * Patient on AME Non-inclusion criteria specific by department: Non-inclusion criteria for Clinical Hematology Department: * Ongoing treatment with high doses (\>1 mg/kg/d) of systemic corticosteroid therapy * Ongoing treatment with JAK inhibitors Non-inclusion criteria for Nephrology and Transplantation Department: * Ongoing treatment with doses \>10 mg/d Prednisone * Ongoing treatment with Cellcept, Endoxan, Imurel, Belimumab, Anti-CD20, Methotrexate * Ongoing treatment with JAK inhibitors Non-inclusion criteria for Neurology Department: * Treatment with systemic corticosteroid therapy, Fingolimod or Teriflunomide * Ongoing treatment with JAK inhibitors * Lymphocytosis \< 0.5 G/L Non-inclusion criteria for Rheumatology Department: * Ongoing treatment with doses \>15 mg/d Prednisone * Treatment with Rituximab or Tocilizumab * Ongoing treatment with JAK inhibitors * Lymphocytosis \< 0.5 G/L Non-inclusion criteria for Internal Medicine - Endocrinology Department: * Ongoing immunosuppressive therapy * Ongoing treatment with JAK inhibitors Non-inclusion criteria for Dermatology Department: * Ongoing treatment with Methotrexate * Ongoing treatment with JAK inhibitors * Ongoing treatment with doses \>10 mg/d prednisone
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| the percentage of phosphorylated STAT5 in LTresg compared to LTconv after incubation with IL-2 muteins | At inclusion | The measurement method is based on the quantification of the phosphorylated STAT5 molecule in LTconv and LTreg by flow cytometry after incubating the cells with IL-2 or IL-2 muteins |
Countries
France
Outcome results
None listed